for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

86.98USD

Change

0.26(+0.30%)

Volume

1,491,817

Today's Range

86.80

 - 

87.70

52 Week Range

62.68

 - 

92.99

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
86.72
Open
87.25
Volume
1,491,817
3M AVG Volume
167.25
Today's High
87.70
Today's Low
86.80
52 Week High
92.99
52 Week Low
62.68
Shares Out (MIL)
1,478.82
Market Cap (MIL)
128,243.40
Forward P/E
9.71
Dividend (Yield %)
5.44

Next Event

Dividend For ABBV.N - 1.1800 USD

Latest Developments

More

Abbvie Reaches An Agreement With Pan-Canadian Pharmaceutical Alliance (pCPA) For Skyrizi (Risankizumab) For Treatment Of Moderate To Severe Plaque Psoriasis

Harpoon Therapeutics, Abbvie Announce Licensing And Option Collaboration To Advance Hpn217, Harpoon's Bcma-Targeting Tritac, And Expand Existing Discovery Collaboration

AbbVie Prices $30 Bln Of Senior Unsecured Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Carlos Alban

Vice Chairman, Chief Commercial Officer

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Senior Vice President

Key Stats

2.09 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

25.6K

2017

28.2K

2018

32.7K

2019(E)

33.3K
EPS (USD)

2016

4.820

2017

5.600

2018

7.910

2019(E)

8.927
Price To Earnings (TTM)
38.83
Price To Sales (TTM)
3.90
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
24.21
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
7.21
Return on Equity (TTM)
5.32

Latest News

Latest News

Belgium's UCB says psoriasis drug beats AbbVie's Humira in trial

UCB SA said on Friday its experimental plaque psoriasis drug produced better results compared to AbbVie Inc's blockbuster drug, Humira, in reducing the severity of the disease.

China's Bio-Thera gets approval for Humira biosimilar

China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market.

AbbVie 2019 revenue forecast tops Wall Street estimates while it eyes future Botox sales

AbbVie Inc <ABBV.N> on Friday forecast 2019 revenue above Wall Street estimates and expressed confidence in future sales of blockbuster wrinkle treatment Botox, which it will acquire with its $63 billion purchase of Allergan Plc <AGN.N>.

AbbVie says multiple parties vying for assets related to Allergan deal approval

AbbVie Inc <ABBV.N> said on Friday it was in talks with several parties interested in buying the two assets it intends to divest for the completion of its $63 billion deal to buy drugmaker Allergan Plc <AGN.N>.

AbbVie lifts 2019 profit forecast as Humira helps beat revenue estimates

AbbVie Inc posted quarterly sales above estimates on Friday and raised the lower end of its 2019 profit forecast, helped by strong demand for cancer medicine Imbruvica and a lower-than-expected drop in bestseller Humira's revenue.

FTC requests AbbVie, Allergan for more information on $63 billion deal

The U.S. Federal Trade Commission (FTC) has requested for more information from AbbVie Inc <ABBV.N> and botox maker Allergan Plc <AGN.N> on their $63 billion deal, the companies said on Friday.

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...

AbbVie abandons late-stage lung cancer asset Rova-T

AbbVie Inc said on Thursday it will cease to develop its experimental drug Rova-T after the treatment failed to show survival benefit in a late-stage trial for a type of lung cancer. The drugmaker acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016...

AbbVie terminates late-stage lung cancer trial

AbbVie Inc on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo.

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

FDA flags serious risks with hepatitis C drugs from AbbVie, Gilead and Merck

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.

AbbVie prices new rheumatoid arthritis drug at $59,000 a year

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

FDA approves AbbVie's new rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc <AGN.N>, which is being bought by AbbVie Inc <ABBV.N> for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc <ABBV.N> said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc <AGN.N> will counter declining sales of its long-time bestseller, Humira.

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc <ABBV.N> said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc <AGN.N>.

AbbVie does not expect to divest new psoriasis drug

AbbVie Inc said on Friday it does not expect the Federal Trade Commission would require divestiture of its recently approved psoriasis drug Skyrizi in connection with the company's $63 billion pending deal to buy Allergan Plc.

AbbVie raises 2019 profit target as quarterly sales beat estimates

Drugmaker AbbVie Inc on Friday raised its earnings forecast for the year and beat Wall Street estimates for second-quarter revenue, as sales of its top-selling drug Humira did not fall as much as analysts had feared.

Samsung Bioepis Humira biosimilar wins FDA approval

(This story corrects to show that Hadlima belongs to Samsung Bioepis not Merck & Co Inc, which is commercializing the drug in the United States)

CORRECTED-US loan market ready to feast on AbbVie's jumbo US$38bn bridge loan

A US$38bn bridge loan backing US biopharmaceutical company AbbVie’s US$63bn bid for Botox-maker Allergan, and the additional bank business the merger will generate, is expected to be welcomed with open arms by a robust US loan market starved of new lending opportunities.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up